Cellma can help you adhere to all NICE guidelines...

Cellma is a bespoke clinical software tool built around the needs of consultants and their clinical teams. It will, save you time, improve patient data and reduce clinical risk management. At RioMed we believe quality of care comes first, to insure this Cellma manages the entire patient care pathway enabling clinicians to access the best possible data always!

Here is how Cellma can help you adhere to the NICE guidelines for Rheumatoid Arthritis:

1.       Referral for specialist treatment:

• Primary and secondary care professionals can share live patient information and instantly make referrals to any specialist or site within the trust (including surgery).
• Cellma will help services create registers of ‘at risk’ patients which has been proven to reduce costs. 

2.       Disease modifying and biological drugs:

• Patient dashboards help track the progress of individual patients and their reaction to specific medications.
• Service dashboards help monitor both overall service performance and the performance of individual medications/procedures that are administered throughout the service.
• Both the above points help clinicians access various avenues of funding for expensive interventions by providing the correct clinical evidence.

 3.       Monitoring disease: 

•  In addition to patient and service dashboards Cellma incorporates fully customisable clinical assessments which can be deployed at various stages in the patient care pathway to aid disease management.
• Monitoring and graphing of CRPs and key components of disease activity (such as DAS28).

 4.       Access to the multidisciplinary team:

• Cellma has been specifically designed to enable clinicians across the care pathway too access live patient data.
• Cellma also has secure mobile capabilities (fully NHS approved) to allow ‘home-visits’ to be recorded.
• As well as automatic referrals Cellma will instantly generate letters that can be followed to relevant parties.  

Please don’t hesitate to contact us for more information: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it